Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd405406.htm |
| EX-99 - PRESS RELEASE, DATED MARCH 13, 2014 - ImmunoCellular Therapeutics, Ltd. | rrd405406_40519.htm |
| Exhibit 99.2 | ||||||||
| Condensed Balance Sheets | ||||||||
| 12/31/2013 | 12/31/2012 | |||||||
|
|
|
|
|
|||||
| Cash and cash equivalents | $ | 27,646,351 | $ | 26,216,668 | ||||
| Other current assets | 763,299 | 714,508 | ||||||
|
|
|
|
|
|||||
| Total current assets | 28,409,650 | 26,931,176 | ||||||
| Non current assets | 531,027 | 88,025 | ||||||
|
|
|
|
|
|||||
| $ | 28,940,677 | $ | 53,950,377 | |||||
|
|
|
|
|
|||||
| Current liabilities | $ | 1,402,273 | $ | 1,098,307 | ||||
| Warrant liabilities | 1,064,810 | 2,852,880 | ||||||
| Shareholders' equity | 26,473,594 | 23,068,014 | ||||||
|
|
|
|
|
|||||
| $ | 28,940,677 | $ | 27,019,201 | |||||
|
|
|
|
|
|||||
| Condensed Statements of Operations | ||||||||
| Year | Year | |||||||
| ended | ended | |||||||
| 12/31/2013 | 12/31/2012 | |||||||
|
|
|
|
|
|||||
| Revenue | $ | - | $ | - | ||||
| Research and development | 5,339,716 | 7,711,233 | ||||||
| Stock based compensation | 724,212 | 496,007 | ||||||
| General and administrative | 3,396,391 | 3,619,291 | ||||||
|
|
|
|
|
|||||
| Loss before other expenses | (9,460,319) | (11,826,531) | ||||||
| Interest income | 17,345 | 8,609 | ||||||
| Financing expense | - | (397,294) | ||||||
| Change in fair value of warrant liabilities | 642,411 | (2,279,923) | ||||||
|
|
|
|
|
|||||
| Net loss | $ | (8,800,563) | $ | (14,495,139) | ||||
|
|
|
|
|
|||||